Amedisys Inc. Stock
Amedisys Inc. Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Amedisys Inc. stock is not clear.
With a target price of 88 € there is a slightly positive potential of 4.14% for Amedisys Inc. compared to the current price of 84.5 €.
So far the community has only identified positive things for Amedisys Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Amedisys Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amedisys Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amedisys Inc. | - | - | - | - | - | - | - |
| Ensign Group Inc. | -1.300% | -4.375% | -7.831% | 12.500% | 20.472% | - | - |
| Amn Healthcare Svs | 1.440% | -1.399% | -17.544% | -43.600% | -38.158% | -87.632% | -73.645% |
| Chemed Corp. | -0.550% | -4.762% | -5.263% | -30.097% | -27.711% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
AMEDISYS INC (AMED) demonstrates a strong financial position as of Q2 2025, with significant revenue and profit growth.
The overall financial trend for AMEDISYS INC is positive, showing growth in revenue and significant improvement in profitability.
Comments
Amedisys, Inc. (NASDAQ: AMED) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
Show more
Ratings data for AMED provided by MarketBeat
Amedisys, Inc. (NASDAQ: AMED) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for AMED provided by MarketBeat
Amedisys, Inc. (NASDAQ: AMED) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for AMED provided by MarketBeat
News
Amedisys (AMED) Q2 Revenue Tops 5%
Amedisys (NASDAQ:AMED), a leading provider of home health, hospice, and high acuity post-acute care services, reported quarterly earnings for the period ending June 30, 2025, on July 29, 2025. The
